AR091739A1 - Composiciones y metodos para reducir el riesgo cardiometabolico - Google Patents

Composiciones y metodos para reducir el riesgo cardiometabolico

Info

Publication number
AR091739A1
AR091739A1 ARP130102472A AR091739A1 AR 091739 A1 AR091739 A1 AR 091739A1 AR P130102472 A ARP130102472 A AR P130102472A AR 091739 A1 AR091739 A1 AR 091739A1
Authority
AR
Argentina
Prior art keywords
compositions
methods
cardiometabolic risk
reduce
reduce cardiometabolic
Prior art date
Application number
Other languages
English (en)
Inventor
S Fineman Mark
D Baron Alain
R A Beeley Nigel
Original Assignee
Elcelyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/547,022 external-priority patent/US8796338B2/en
Priority claimed from US13/734,966 external-priority patent/US9211263B2/en
Application filed by Elcelyx Therapeutics Inc filed Critical Elcelyx Therapeutics Inc
Publication of AR091739A1 publication Critical patent/AR091739A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Composiciones y métodos que comprenden por lo menos un compuesto biguanida y por lo menos una estatina en combinación con por lo menos un agente activo adicional en combinaciones de dosis fijas para reducir el riesgo cardiometabólico, y para el tratamiento de la enfermedad cardiovascular, en donde el compuesto biguanida está formulado para una liberación retardada.
ARP130102472 2012-07-11 2013-07-11 Composiciones y metodos para reducir el riesgo cardiometabolico AR091739A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/547,022 US8796338B2 (en) 2011-01-07 2012-07-11 Biguanide compositions and methods of treating metabolic disorders
US13/734,966 US9211263B2 (en) 2012-01-06 2013-01-05 Compositions and methods of treating metabolic disorders

Publications (1)

Publication Number Publication Date
AR091739A1 true AR091739A1 (es) 2015-02-25

Family

ID=48833086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102472 AR091739A1 (es) 2012-07-11 2013-07-11 Composiciones y metodos para reducir el riesgo cardiometabolico

Country Status (9)

Country Link
EP (1) EP2872127A1 (es)
JP (2) JP2015522080A (es)
CN (1) CN104780915A (es)
AR (1) AR091739A1 (es)
AU (1) AU2013290100A1 (es)
CA (1) CA2878625A1 (es)
HK (1) HK1210825A1 (es)
IL (1) IL236647A0 (es)
WO (1) WO2014011926A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307577A (zh) 2009-02-13 2012-01-04 贝林格尔.英格海姆国际有限公司 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PL2986304T3 (pl) 2013-04-18 2022-05-02 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
WO2019128991A1 (en) * 2017-12-26 2019-07-04 Sunshine Lake Pharma Co., Ltd. Lurasidone solid dispersion and preparation method thereof

Family Cites Families (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS58403B2 (ja) 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
FR2704146B1 (fr) 1993-04-19 1995-07-13 Cripdom Microcapsules d'acide acétylsalicylique à libération contrôlée.
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
DE69836321T2 (de) 1997-04-15 2007-06-28 Csir, Pretoria Pflanzenextrakte mit appetitzügelnder Aktivität
US5891919A (en) 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US6180365B1 (en) 1998-11-06 2001-01-30 Smithkline Beecham Corporation Polynucleotide encoding a Mouse 7-transmembrane GPR43 receptor
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
IL132313A0 (en) 1999-10-11 2001-03-19 Yeda Res & Dev Leptin assay
EP1255779A2 (en) 2000-02-18 2002-11-13 Glaxo Group Limited Identification of modulators of gpr41 or gpr42 activity
US20110217394A1 (en) 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
US7998947B2 (en) 2001-03-28 2011-08-16 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
US8030008B2 (en) 2001-04-05 2011-10-04 Senomyx, Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
JP4360915B2 (ja) 2002-01-07 2009-11-11 ユーロスクリーン・ソシエテ・アノニム Ｇタンパク質共役受容体ｇｐｒ４３のリガンドおよびその使用
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US20060019346A1 (en) 2002-07-29 2006-01-26 Senomyx, Inc. Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands
WO2004012715A1 (en) * 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
CN1720046A (zh) 2002-10-10 2006-01-11 阿伦纳药品公司 作为抗脂解药用于治疗血脂异常等代谢相关疾病的5－取代的2h－吡唑－3－甲酸衍生物
AU2003273994A1 (en) 2002-10-25 2004-05-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
AU2003267443A1 (en) 2002-10-25 2004-05-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
CN1413582A (zh) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 盐酸二甲双胍肠溶片及其制备方法
JP4654038B2 (ja) 2002-12-18 2011-03-16 ジボダン エス エー キメラアルファｑ−ガストデューシンｇタンパク質
WO2004072650A1 (en) 2003-02-17 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 40 (gpr40)
DE10308504A1 (de) 2003-02-26 2004-09-09 Basf Ag Enzymatische Herstellung von (Meth)acrylsäureestern
WO2004106276A1 (ja) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited 縮合環化合物
WO2005011677A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
WO2005009351A2 (en) 2003-07-17 2005-02-03 Santé International, Inc. Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabetics
AU2003269484A1 (en) * 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
WO2005028488A1 (en) 2003-09-12 2005-03-31 Quatrx Pharmaceuticals Co. Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
AU2004293415A1 (en) 2003-11-21 2005-06-09 Arena Pharmaceuticals, Inc. 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
CA2551610A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
WO2005095338A1 (ja) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
EP1737442B1 (en) 2004-04-20 2015-01-07 Deutsches Institut Für Ernährungsforschung - Stiftung Des Öffentlichen Rechts - Vertreten Durch Den Stiftungsvorstand Agonists of a bitter taste receptor and uses thereof
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
US20060024335A1 (en) 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
WO2006036688A2 (en) 2004-09-22 2006-04-06 Arena Pharmaceuticals, Inc. Gpr43 and modulators thereof for the treatment of metabolic-related disorders
JPWO2006038738A1 (ja) 2004-10-08 2008-05-15 武田薬品工業株式会社 受容体機能調節剤
EP1812080B1 (en) 2004-11-03 2014-07-09 Arena Pharmaceuticals, Inc. Gpr41 and modulators thereof for the treatment of insulin-related disorders
US7829299B2 (en) 2004-11-18 2010-11-09 Deutsches Institut fur Ernahrungforschung Potsdam-Rehbrucke Stiftung des Offentlichen Rechts Agonists of bitter taste receptors and uses thereof
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
JP2008528590A (ja) 2005-01-28 2008-07-31 メルク エンド カムパニー インコーポレーテッド 抗糖尿病性二環式化合物
EP1846379B1 (en) 2005-01-31 2009-08-19 Merck & Co., Inc. Antidiabetic bicyclic compounds
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
WO2006102653A2 (en) 2005-03-24 2006-09-28 Irm Llc Methods and compositions for treating insulin resistance and obesity-induced diseases
KR20080004632A (ko) 2005-04-28 2008-01-09 아지노모토 가부시키가이샤 신규 락탐 화합물
WO2006127595A1 (en) 2005-05-23 2006-11-30 Arena Pharmaceuticals, Inc. 5-aminopyrazole carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof
US20060269617A1 (en) 2005-05-26 2006-11-30 Suracell, Inc. Supplement compositions and method of use for enhancement of insulin sensitivity
JP2009501317A (ja) 2005-06-22 2009-01-15 セノミクス・インコーポレーテッド コーヒー中の苦味分子（クロロゲン酸ラクトン）により活性化されるヒトｔ２ｒ受容体の同定、およびヒト苦味味覚モジュレーターを同定するための関連するアッセイ
CN101218250A (zh) 2005-07-28 2008-07-09 雀巢技术公司 脂肪味觉受体及其使用方法
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1924709A1 (en) 2005-08-10 2008-05-28 Arena Pharmaceuticals, Inc. Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist
JP4932724B2 (ja) 2005-09-02 2012-05-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｇｐｒ１２０とホスホリパーゼとを用いる疾患に有用な物質のスクリーニング方法
WO2007049050A2 (en) 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
US20070104805A1 (en) 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
JP2007215162A (ja) 2006-01-11 2007-08-23 Canon Inc 情報処理装置及びその制御方法、プログラム、記憶媒体
US20070207227A1 (en) 2006-02-23 2007-09-06 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Appetite suppressant compositions
NZ571869A (en) 2006-04-06 2011-11-25 Prosidion Ltd Heterocyclic GPCR agonists
WO2007116404A2 (en) 2006-04-10 2007-10-18 Bar-Ilan University Cucurbitacin glucosides and use thereof in treating cancer
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
JP4521838B2 (ja) 2006-04-11 2010-08-11 アリーナ ファーマシューティカルズ， インコーポレイテッド 個体において骨質量を増加させるために有用である化合物を同定するためにｇｐｒ１１９受容体を用いる方法
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
ATE552245T1 (de) 2006-05-15 2012-04-15 Merck Sharp & Dohme Antidiabetische bicyclische verbindungen
WO2007134613A1 (en) 2006-05-24 2007-11-29 Rheoscience A/S Modulation of gpr120 activity in adipocytes/fat tissue
TWI354668B (en) 2006-06-27 2011-12-21 Takeda Pharmaceutical Fused cyclic compounds
CA2551706A1 (en) 2006-06-27 2007-12-27 Innovative Life Sciences Corporation Herbal product comprising cinnamon and bitter melon
CN100596277C (zh) 2006-07-10 2010-03-31 博仲盛景医药技术（北京）有限公司 一种促进肠胃蠕动的药物组合物
CN101511429A (zh) 2006-07-13 2009-08-19 史密丝克莱恩比彻姆公司 二氢吲哚衍生物和gpr119激动剂
CA2660464A1 (en) 2006-08-17 2008-02-21 Unilever Plc Processes for production of hoodia plant extracts containing steroidal glycosides
AP2009004773A0 (en) 2006-08-24 2009-02-28 Unilever Plc Process for preparing a composition comprising steroidal glycosides
AU2007291252A1 (en) 2006-08-30 2008-03-06 Inovacia Ab Pyridine compounds for treating GPR119 related disorders
US7811788B2 (en) 2006-09-05 2010-10-12 Senomyx Inc. Nucleic acid encoding a haplotype of human T2R receptor hT2R50
AU2007293028B2 (en) 2006-09-07 2012-05-31 Amgen Inc. Heterocyclic GPR40 modulators
WO2008063321A2 (en) 2006-10-13 2008-05-29 Janssen Pharmaceutica N.V. Gpr81-ligand complexes and their preparation and use
WO2008054674A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
WO2008054675A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
BRMU8602999U (pt) * 2006-11-16 2008-07-08 Walter Junior Santos medicamento "rosuvastatina + metformina" em forma combinada para doenças cardiovasculares
WO2008058355A2 (en) * 2006-11-16 2008-05-22 Walter Santos Junior Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases
CN101190179B (zh) * 2006-11-20 2010-05-12 北京利龄恒泰药业有限公司 一种治疗糖尿病的肠溶药物组合物及其制备方法
TW200838526A (en) 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
US8367708B2 (en) 2006-12-01 2013-02-05 Msd K.K. Phenyl-isoxazol-3-ol derivative
US8058312B2 (en) * 2007-01-29 2011-11-15 Hanall Biopharma Co., Ltd. N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
KR20090113382A (ko) 2007-02-22 2009-10-30 아이알엠 엘엘씨 Ｇ 단백질-커플링된 수용체의 조절제로서의 티아졸 유도체
BRPI0808775A2 (pt) 2007-03-08 2017-05-30 Irm Llc compostos e composições como moduladores de atividade de gpr119
EP1975611A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
EP1975612A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
AU2008241490B2 (en) 2007-04-16 2011-07-21 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators
CN102015677A (zh) 2007-04-20 2011-04-13 先灵公司 嘧啶酮衍生物及其使用方法
EP2148679A1 (en) 2007-04-20 2010-02-03 Schering Corporation Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof
JP2010524941A (ja) 2007-04-20 2010-07-22 シェーリング コーポレイション ピリミジノン誘導体およびそれらの使用方法
JP5420400B2 (ja) 2007-04-26 2014-02-19 国立大学法人京都大学 Ｇタンパク質共役型レセプター作動剤
CN101668756A (zh) 2007-05-04 2010-03-10 百时美施贵宝公司 [6,6]和[6,7]-双环gpr119 g蛋白偶合受体激动剂
CN101668759A (zh) 2007-05-04 2010-03-10 百时美施贵宝公司 [6,5]-双环gpr119g蛋白-偶合受体激动剂
WO2008144423A2 (en) 2007-05-15 2008-11-27 Medical College Of Georgia Research Institute, Inc. Compositions comprising a gpr109 ligand for treating disorders of the digestive tract and/or cancer
US7928230B2 (en) 2007-07-17 2011-04-19 Bristol-Myers Squibb Company Method for modulating GPR119 G protein-coupled receptor and selected compounds
KR20100033419A (ko) 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
US20090042813A1 (en) 2007-08-10 2009-02-12 Sergey Michailovich Melnikov Hoodia extract oil compositions comprising medium chain triglycerides
WO2009033078A2 (en) 2007-09-05 2009-03-12 Raif Tawakol Compositions and methods for controlling cholesterol levels
JP2010539152A (ja) 2007-09-10 2010-12-16 プロシディオン・リミテッド 代謝障害の治療のための化合物
WO2009038204A1 (ja) 2007-09-17 2009-03-26 Pharma Frontier Co., Ltd. 新規長鎖脂肪酸誘導体化合物及びそれら化合物を有効成分とするｇタンパク質共役型レセプター作動剤
NZ583495A (en) 2007-09-20 2011-11-25 Irm Llc Compounds and compositions as modulators of gpr119 activity
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
AU2008317057B8 (en) 2007-10-22 2014-02-13 Merck Sharp & Dohme Corp. Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
JP2011016722A (ja) 2007-10-23 2011-01-27 Astellas Pharma Inc チアゾリジンジオン化合物
WO2009053980A2 (en) 2007-10-24 2009-04-30 Arava Hoodia Growers A. C. S. Ltd. An improved appetite suppressant
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
EP2215068B1 (en) 2007-10-29 2012-06-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
DK2236149T3 (da) 2008-01-29 2014-08-25 Nakamori Pharmaceutical Co Ltd Medicinsk sammensætning til behandling af respiratoriske infektions-sygdomme
EA201001332A1 (ru) 2008-02-22 2011-04-29 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
CN102007126A (zh) 2008-02-22 2011-04-06 Irm责任有限公司 作为gpr119活性调控剂的化合物和组合物
EA201001330A1 (ru) 2008-02-22 2011-04-29 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
WO2009106565A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Agonists of gpr119
WO2009106561A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
KR20100134659A (ko) 2008-03-31 2010-12-23 메타볼렉스, 인코포레이티드 옥시메틸렌 아릴 화합물 및 그것의 사용
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US20110263557A1 (en) 2008-04-07 2011-10-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009125804A1 (ja) 2008-04-09 2009-10-15 武田薬品工業株式会社 スクリーニング方法
JP2011520969A (ja) 2008-05-19 2011-07-21 シェーリング コーポレイション 二環式ヘテロ環誘導体およびｇｐｒ１１９モジュレーターとしてのその使用
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
US9844224B2 (en) 2008-05-23 2017-12-19 Givaudan Sa Bitter alkaloid containing consumables comprising bitter blockers
US20110071198A1 (en) 2008-05-27 2011-03-24 Lefkowitz Robert J Nicotinic acid receptor ligands
CN101695575A (zh) * 2008-05-29 2010-04-21 北京奥萨医药研究中心有限公司 含有他汀类降脂药物、双胍类降糖药物和烟酸的药物组合物
JPWO2009147990A1 (ja) 2008-06-02 2011-10-27 Ｍｓｄ株式会社 新規イソオキサゾール誘導体
WO2009150144A1 (en) 2008-06-10 2009-12-17 Inovacia Ab New gpr119modulators
EP2300830B1 (en) 2008-06-13 2015-05-20 Givaudan SA Methods of identifying modulators of the bitter taste receptor tas2r44
US20110294836A1 (en) 2008-06-20 2011-12-01 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
GB0812031D0 (en) 2008-07-01 2008-08-06 7Tm Pharma As Thiazole derivatives
GB0812649D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
EP2331503B1 (en) 2008-07-11 2013-08-21 Irm Llc 4-phenoxymethylpiperidines as modulators of gpr119 activity
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
EP2318404B1 (en) 2008-07-16 2013-08-21 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
EP2313360B1 (en) 2008-07-28 2012-09-05 Syddansk Universitet Compounds for the treatment of metabolic diseases
WO2010013849A1 (ja) 2008-08-01 2010-02-04 日本ケミファ株式会社 Ｇｐｒ１１９作動薬
EP2329271B1 (en) 2008-08-29 2012-06-20 Givaudan SA Methods to identify modulators
EP2330103B1 (en) 2008-08-29 2015-10-07 Suntory Holdings Limited Novel epigallocatechin gallate tetramer, and vascular endothelial function improver comprising same
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2690095A1 (en) 2008-10-21 2014-01-29 Camabay Therapeutics, Inc. Aryl gpr120 receptor agonists and uses thereof
WO2010060198A1 (en) 2008-11-26 2010-06-03 West Central Envirotech Inc. Composition and method for controlling insects
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010074271A1 (ja) 2008-12-26 2010-07-01 武田薬品工業株式会社 糖尿病治療剤
KR101615876B1 (ko) 2009-01-03 2016-04-27 시즈오까껭 고리쯔다이가꾸호징 황산화 ｃ―배당체 및 이의 단리 방법 및 합성 방법
WO2010084944A1 (ja) 2009-01-22 2010-07-29 田辺三菱製薬株式会社 新規ピロロ［２，３－ｄ］ピリミジン化合物
CA2749891A1 (en) 2009-01-23 2010-07-29 Hubert B. Josien Bridged and fused antidiabetic compounds
US20110313008A1 (en) 2009-01-23 2011-12-22 Schering Corporation Pentafluorosulpholane-containing antidiabetic compounds
EP2389226B1 (en) 2009-01-23 2013-11-20 Merck Sharp & Dohme Corp. Bridged and fused heterocyclic antidiabetic compounds
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US8575166B2 (en) 2009-02-05 2013-11-05 Merck Sharp & Dohme Corp. Phthalazine-containing antidiabetic compounds
WO2010095663A1 (ja) 2009-02-18 2010-08-26 武田薬品工業株式会社 縮合複素環化合物
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
WO2010106457A2 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
JP2012136438A (ja) 2009-04-22 2012-07-19 Astellas Pharma Inc テトラゾール化合物
TW201103535A (en) 2009-04-22 2011-02-01 Astellas Pharma Inc Carboxylic acid compounds
JP2012136439A (ja) 2009-04-24 2012-07-19 Nippon Chemiphar Co Ltd ジアザスピロアルカン誘導体
WO2010128425A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
JP2012526096A (ja) 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子
KR20120061063A (ko) 2009-06-05 2012-06-12 화이자 인코포레이티드 Ｇｐｒ 119 조절제로서의 ｌ-(피페리딘-4-일)-피라졸 유도체
US20120172351A1 (en) 2009-06-09 2012-07-05 Nobuyuki Negoro Novel fused cyclic compound and use thereof
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
AR077638A1 (es) 2009-07-15 2011-09-14 Lilly Co Eli Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
EP2460010A1 (en) 2009-07-28 2012-06-06 Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke Agonists and antagonists of human bitter taste receptor tas2r49 and uses thereof
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
US20120245344A1 (en) 2009-08-31 2012-09-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
CA2772618C (en) 2009-09-01 2018-08-21 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
WO2011036576A1 (en) 2009-09-23 2011-03-31 Pfizer Inc. Gpr 119 modulators
WO2011044139A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Fatty acid acifran derivatives and their uses
US20110082156A1 (en) 2009-10-05 2011-04-07 Milne Jill C Fatty acid acipimox derivatives and their uses
KR20120104534A (ko) 2009-10-06 2012-09-21 브리스톨-마이어스 스큅 컴퍼니 피롤리딘 ｇｐｒ40 조절제
IN2012DN02471A (es) 2009-10-09 2015-08-21 Irm Llc
EP2488180A4 (en) * 2009-10-12 2013-03-27 Ipca Lab Ltd PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT / PROPHYLAXIS OF NON ALCOHOLIC HEPATIC STEATOSIS
US8349818B2 (en) 2009-10-21 2013-01-08 Wisconsin Alumni Research Foundation Method of preventing Type 1 diabetes
CA2778684A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
JPWO2011052756A1 (ja) 2009-10-30 2013-03-21 持田製薬株式会社 新規３−ヒドロキシ−５−アリールイソキサゾール誘導体
WO2011057110A1 (en) 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia
WO2011055770A1 (ja) 2009-11-06 2011-05-12 武田薬品工業株式会社 縮合複素環化合物
EP2504342A1 (en) 2009-11-23 2012-10-03 Pfizer Inc. Imidazo-pyrazoles as gpr119 inhibitors
EP2503887B1 (en) 2009-11-24 2016-01-06 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
EP2506933A1 (en) 2009-12-04 2012-10-10 Colgate-Palmolive Company Oral compositions containing extracts of garcinia mangostana l. and related methods
EP2332427A1 (en) 2009-12-07 2011-06-15 Nestec S.A. low caloric fat replacers
WO2011072132A1 (en) 2009-12-09 2011-06-16 The Regents Of The University Of California Methods of treating inflammatory conditions
EP3255038A1 (en) 2009-12-18 2017-12-13 Ogeda Sa Pyrrolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disorders as agonists of g-protein coupled receptor 43 (gpr43)
JP2013047188A (ja) 2009-12-24 2013-03-07 Nippon Chemiphar Co Ltd Ｇｐｒ１１９作動薬
EP2518060A4 (en) 2009-12-25 2014-01-08 Mochida Pharm Co Ltd NEW 3-HYDROXY-5-ARYLISOTHIAZOL DERIVATIVE
EP2345646A1 (en) 2010-01-14 2011-07-20 InterMed Discovery GmbH Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
WO2011092284A1 (en) 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Ｇｐｒ119 작동약
CN101785763B (zh) * 2010-02-04 2011-11-23 贵州天安药业股份有限公司 一种盐酸二甲双胍肠溶缓释片及其制备方法
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
US20130023494A1 (en) 2010-04-06 2013-01-24 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2556069B1 (en) 2010-04-08 2015-04-01 Bristol-Myers Squibb Company 4-(1-(pyrimidin-2-yl)piperidin-4-yloxy)pyridin-2-one compounds as gpr119 modulators
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
MX2012012902A (es) 2010-05-06 2012-12-17 Bristol Myers Squibb Co Analogos heteroarilo biciclicos como moduladores de receptor acoplado a la proteina g gpr119.
US8772323B2 (en) 2010-05-07 2014-07-08 Boehringer Ingelheim International Gmbh Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists
CA2799779A1 (en) 2010-05-17 2011-11-24 Thomas Daniel Aicher Piperidinyl-substituted lactams as gpr119 modulators
WO2011145718A1 (ja) 2010-05-21 2011-11-24 田辺三菱製薬株式会社 新規ピロロ［２，３－ｄ］ピリミジン化合物
TW201202230A (en) 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US20110293753A1 (en) 2010-05-28 2011-12-01 Louis Bellafiore Tocotrienol Compositions
WO2011151436A2 (en) 2010-06-04 2011-12-08 Euroscreen S.A. Novel compounds, method for use them and pharmaceutical composition containing them
GB201009873D0 (en) 2010-06-14 2010-07-21 Univ Leuven Kath Method for hydrogenation of isoalpha-acids (isohumulones) to hexahydro-iso-alpha-acids (hexahydro-isohumulones) by using heterogeneous ruthenium
CA2801182A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
US20130096141A1 (en) 2010-06-18 2013-04-18 Bernard R. Neustadt Bicyclic heterocycle derivatives and methods of use thereof
EP2397039A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Compositions for delaying progression of diabetes using Salacia oblonga extract
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012006955A1 (en) 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. Compounds for treatment of metabolic disorders
KR20120011357A (ko) 2010-07-23 2012-02-08 현대약품 주식회사 치환된 피리디논 유도체 및 이의 제조방법
IN2013CN01340A (es) 2010-07-23 2015-08-07 Connexios Life Sciences Pvt Ltd
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
EP2616074A1 (en) 2010-09-17 2013-07-24 Array Biopharma, Inc. Piperidinyl-substituted lactams as gpr119 modulators
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
CN102432598A (zh) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
JP5814377B2 (ja) 2010-10-08 2015-11-17 カディラ ヘルスケア リミティド 新規ｇｐｒ１１９アゴニスト
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
JP2014001144A (ja) 2010-10-08 2014-01-09 Nippon Chemiphar Co Ltd Ｇｐｒ１１９作動薬
CN101978956B (zh) * 2010-10-13 2012-03-28 北京京丰制药有限公司 盐酸二甲双胍肠溶片及其制备方法
KR20140027910A (ko) 2010-10-30 2014-03-07 킨덱스 테라퓨틱스, 엘엘씨 시스 3,4-디히드록시-2-(3-메틸부타노일)-5-(3-메틸부틸)-4-(4-메틸펜타노일)시클로펜트-2-엔-1-온 유도체, 실질적으로 거울상이성질체적으로 순수한 조성물, 및 방법
CN103298801A (zh) 2010-11-23 2013-09-11 辉瑞大药厂 作为gpr 119 调节剂的4-（5-氰基-吡唑-1-基）哌啶衍生物
WO2012069917A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
EP2646425B1 (en) 2010-12-01 2015-06-10 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome
WO2012077655A1 (ja) 2010-12-07 2012-06-14 塩野義製薬株式会社 Ｇｐｒ１１９アゴニスト活性を有するスピロ誘導体
UY33805A (es) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
US8853213B2 (en) 2011-01-03 2014-10-07 Hanmi Pharm. Co., Ltd Bicyclic compound for modulating G protein-coupled receptors
CN103443097A (zh) 2011-01-21 2013-12-11 勃林格殷格翰国际有限公司 作为gpr119调节剂用于治疗糖尿病、肥胖症以及相关病症的稠合的二氢呋喃化合物
CN102617548A (zh) 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
TW201309639A (zh) 2011-02-17 2013-03-01 Lg Life Sciences Ltd 作為ｇｐｒ１１９促效劑之肟衍生物
US8822471B2 (en) 2011-03-14 2014-09-02 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012136221A1 (en) 2011-04-08 2012-10-11 Syddansk Universitet Ortho-fluoro substituted compounds for the treatment of metabolic diseases
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
RU2013152631A (ru) 2011-04-27 2015-06-10 Мотида Фармасьютикал Ко., Лтд. Новое 3-гидроксиизотиазол-1-окидное производное
EP2716636A4 (en) 2011-04-28 2014-11-26 Mochida Pharm Co Ltd CYCLIC AMIDE DERIVATIVE
KR101401496B1 (ko) 2011-05-12 2014-06-11 한국화학연구원 티에노피리미딘 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 관련 질환의 예방 또는 치료용 약학적 조성물
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2718288B1 (en) 2011-06-09 2015-03-11 Boehringer Ingelheim International GmbH Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders
JP2014159376A (ja) 2011-06-17 2014-09-04 Taisho Pharmaceutical Co Ltd アザスピロアルカン化合物
EP2731944A1 (en) 2011-07-15 2014-05-21 Pfizer Inc Gpr 119 modulators
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102357088A (zh) * 2011-10-26 2012-02-22 河北山姆士药业有限公司 盐酸二甲双胍肠溶片

Also Published As

Publication number Publication date
IL236647A0 (en) 2015-02-26
AU2013290100A1 (en) 2015-01-29
WO2014011926A1 (en) 2014-01-16
CA2878625A1 (en) 2014-01-16
HK1210825A1 (en) 2016-05-06
JP2015522080A (ja) 2015-08-03
JP2018087214A (ja) 2018-06-07
EP2872127A1 (en) 2015-05-20
CN104780915A (zh) 2015-07-15

Similar Documents

Publication Publication Date Title
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
GT201200276A (es) Combinaciones de compuestos activos
CL2014000601A1 (es) Composición tópica veterinaria que comprende al menos un agente activo derivado de isoxazolina; y uso de la composición para el tratamiento o prevención de una infestación o infección por parásitos en un animal.
CL2014002087A1 (es) Composición veterinaria masticable que comprende como agente activo un compuesto derivado de isoxazolina; y su uso para el tratamiento y/o prevención de una infestación y/o infección por parásitos en un animal.
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
BR112012023021A2 (pt) compostos de indazol e seus usos
CU24336B1 (es) Compuestos de imidazopirrolidinona
DOP2016000253A (es) Nuevos compuestos
UY33598A (es) Imidazopiridazinas sustituidas
CL2015001389A1 (es) Composiciones y compuestos antihelmínticos y métodos para usarlos.
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
NI201500118A (es) Imidazopiridazinas sustituidas
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
DOP2016000007A (es) Pirazolpiridinas sustituidas
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2017001239A1 (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos. (divisional solicitud 2831-2014)
CO6551731A2 (es) Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica
CL2016000300A1 (es) Métodos terapéuticos
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.
CL2014002401A1 (es) Composicion de accion prolongada que incluye un agente bioactivo, un portador no acuoso, aceite de ricino y al menos una amida ciclica; metodo de preparacion; uso para prevenir o tratar una infeccion parasitaria en un animal.

Legal Events

Date Code Title Description
FB Suspension of granting procedure